BILATERAL BLINDNESS DUE TO ANTI-TUBERCULAR TREATMENT: A RARE PRESENTATION

SULATHA V BHANDARY1, AKSHAY SEHGAL1*, LAVANYA G RAO2, KRISHNA RAO A1, PALLAK KUSUMGAR1, HARISH THANUSUBRAMANIAN3

1Department of Ophthalmology, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India. 2Department of Ophthalmology, Srinivas Institute of Medical Sciences and Research Centre, RGUHS, Mangalore - 575 021, Karnataka, India. 3Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India. Email: akshaysehgal08@gmail.com

ABSTRACT

Ethambutol and isoniazid (INH) are antimicrobial agents used in the treatment of tuberculosis. Optic neuropathy is a well-recognized toxic effect of these drugs, usually manifesting as a decrease in visual acuity and deficits in color vision. This study presents the case of a 75-year-old male diagnosed of spinal tuberculosis, who developed irreversible bilateral optic neuropathy causing complete blindness induced by ethambutol and INH. Ophthalmologic examination revealed sluggish pupillary reactions and optic disc pallor in both eyes. Visual evoked potential and magnetic resonance imaging brain complemented the confirmation of the diagnosis.

Keywords: Ethambutol, Isoniazid, Optic neuritis, Tuberculosis.

INTRODUCTION

Tuberculosis is the most common cause of infectious disease-related mortality worldwide [1]. Ethambutol and isoniazid (INH) are synthetic first-line agents of the anti-tubercular treatment (ATT) against Mycobacterium tuberculosis. Ethambutol optic neuropathy is a well-recognized adverse ocular event in patients who receive the drug for the treatment of mycobacterial infections [2]. However, most cases in literature are reversible [3]. Optic nerve involvement is a rare side-effect of INH [4]. We, hereby, report a very rare event of bilateral total blindness due to ATT.

CASE REPORT

A 75-year-old man presented with a sudden decrease in vision in both eyes since 8 days which progressed to an inability to recognize faces. Over 8 days, vision loss progressed to no perception of light in both eyes. He had been on ATT for tuberculosis of spine for 3 months after which he developed ATT-induced hepatitis for which ATT was temporarily withdrawn. After 1 week, ethambutol, INH, streptomycin, and levofloxacin were re-started (but not pyrazinamide and rifampin due to their hepatotoxic side-effects). Following this, ATT was continued for 2 more months and then it was stopped again once the patient developed optic neuropathy.

His visual acuity was the absence of perception of light in both eyes. Examination of both eyes revealed ill-sustained pupillary reactions to light. Intraocular pressure in both eyes was normal. On fundus examination (Fig.1), an optic disc of both eyes had diffuse pallor, more temporal side with clear margins suggestive of primary optic atrophy. Visual evoked potential (VEP) showed the absence of waveforms in both eyes, confirming optic nerve pathology. Magnetic resonance imaging (MRI) brain showed hyperintensity of T2 flair with opticochiasmatic arachnoiditis.

ATT was discontinued and the patient was started on intramuscular injections of vitamin B1 500 mg, vitamin B6 25 mg, and vitamin B12 0.5 mg for 1 week. This was followed by oral supplementation of vitamins. He was also started on intravenous high-dose methylprednisolone 500 mg twice daily for 5 days followed by oral steroids (1 mg/kg) for the next 11 days. The dose of oral steroids was then gradually tapered off. At the time of discharge, vision was still no perception of light, and the optic disc was pale in both eyes. On follow-up visits at 1 and 3 months, there was no improvement in the vision noted.

DISCUSSION

Visual loss due to optic neuropathy is a rare side-effect of ATT particularly ethambutol and INH [5]. Although INH may also be responsible, ethambutol-associated optic neuropathy is more widely recognized [6]. Typical signs of ATT-induced optic neuritis include sudden onset vision loss, sluggish pupils, and pallor of the optic disc. MRI and VEP complement the confirmation of the diagnosis. However, the most cases documented in literature are reversible with pyridoxine, steroids and stoppage of ATT [4]. Moreover, such severe bilateral irreversible loss of vision is very rarely seen. Hence, clinicians should be well aware of the occurrence of such reactions to ATT. All patients on ATT should undergo regular ophthalmological evaluation before and during the course of treatment.
REFERENCES